Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer.

ABSTRACT:

Background

Radium-223 dichloride (Ra-223) is a targeted alpha therapy that induces localized cytotoxicity in bone metastases. We evaluated the efficacy and safety of Ra-223 plus hormonal therapy in hormone receptor-positive (HR+), bone-dominant metastatic breast cancer.

Methods

In this single-center phase II study, 36 patients received Ra-223 (55 kBq/kg intravenously every 4 weeks) up to 6 cycles with endocrine therapy. The primary objective was to determine the clinical disease control rate at 9 months. Secondary objectives were to determine (a) tumor response rate at 6 months, (b) progression-free survival (PFS) durations, and (c) safety.

Results

The median number of prior systemic treatments for metastatic disease was 1 (range, 0-4). The disease control rate at 9 m

SUBMITTER: Ueno NT 

PROVIDER: S-EPMC6997080 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature